What is notnotch therapeutics? Notch Therapeutics is an immune cell therapy company developing a pipeline of off-the-shelf, genetically tailored T cell therapeutics. It is derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.What is notch t cell technology? The aim of Notch is to generate T cells from multiple sources of stem cells and provide a platform for research and development, and a better way of manufacturing T cells and their applications for treating cancers or immune deficiencies.What is notchs relationship with allogene therapeutics? Notch has an existing partnership with Allogene Therapeutics to apply Notch’s proprietary ETN platform to develop CAR-targeted, iPSC-derived, off-the-shelf T cell or natural killer (NK) cell therapies for hematologic cancer indications.What is notnotchs immunotherapy pipeline? Notch is developing a pipeline of cellular immunotherapies originating from pluripotent stem cells that are specifically engineered to address the underlying biology of complex disease systems.
All Notch Therapeutics Locations. Toronto (HQ) Canada. 2100-40 King St W. Vancouver. Canada. Pharmaceutical Sciences Building, 2405 Wesbrook Mall 4th floor. Report incorrect company information. Location of similar companies.
About us. Notch is an immune cell therapy company developing a next-generation pipeline of off-the-shelf, universally compatible, genetically tailored T cell therapeutics derived from renewable
Bond joined Notch with more than 18 years of experience working with biotechnology and pharmaceutical companies including Genentech, OncoMed, Juno Therapeutics, Celgene, and Kite. Dr. Bond has extensive experience in the discovery and development of adoptive cell therapies, monoclonal antibodies, and cellular engineering and genome editing.
FOUNDING INSTITUTIONS. Notch was founded in 2018 by Sunnybrook Research Institute and the University of Toronto, in conjunction with Toronto Innovation Acceleration Partners and the Centre for Commercialization of Regenerative Medicine in Toronto.
Notch Therapeutics raises $85M for cancer treatments and plans to open Seattle location New funding: Notch Therapeutics has raised a $85 million Series A round, bringing its total funding to $91 million. The biotech company was founded in 2018 and is developing stem cell-derived immunotherapies for cancer.